On the most recent trading day, Abbott’s shares fell 1.43%, underperforming the S&P 500’s 0.92% decline as investors reacted to mixed sector data and macroeconomic uncertainty. Trading volume climbed to 18 million shares, nearly 20% above its 30-day average of 15 million, suggesting heightened investor interest. The stock’s one-month volatility has increased to 22%, up from 18% three months ago, reflecting growing market sensitivity to the company’s near-term growth drivers.

Consensus analyst forecasts for the quarter ended December 2025 call for revenue of $10.5 billion, a 5.2% increase year-over-year, and adjusted EPS of $1.30, representing 6.5% growth. Wall Street’s top five estimates range from $10.3 billion to $10.7 billion in revenue and $1.27 to $1.33 in EPS. Key operational drivers include an expected gross margin of 64.0%, up from 63.2% a year earlier, and R&D spending projected to rise by 8% to $1.1 billion as the company advances its cardiovascular and diabetes product pipeline. Abbott’s Zacks Rank currently stands at #2 (Buy), part of a stock-rating system that has delivered an average annual gain of +23.90% since 1988.